TrueCAGR

Biocon Ltd.

NSE: BIOCONBSE: 532523ISIN INE376G01013Face value ₹5consolidated
₹366
+1.01% · 2026-11-20 · 52-wk ₹327–₹441
Source: BSE filings · Financials to FY2026 · 8 years of history · Data last updated: results filed 4 Nov 2026, prices to 20 Nov 2026 · How we calculate thisconsolidatedstandalone
Section 02 · Synthesis

What stands out?

The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.

StrengthConcernWatchContext
WatchTalking point

Profit lagging revenue

Revenue grew 10.9% but profit declined 74.2%, so the company kept less of each rupee of revenue as profit.

Revenue growth+10.9%Net profit growth−74.2%

Importance 74 / 95 · growth

WatchTalking point

Sharp margin drop

EBITDA margin dropped 6.2 percentage points in a single year, from 28.7% to 22.4% — worth investigating.

Importance 70 / 95 · anomaly

ConcernTalking point

Capital efficiency slipping

ROCE has fallen for 6 consecutive years, from 13.6% to 3.8%.

Importance 69 / 95 · profitability

WatchTalking point

Premium valuation, soft growth

The P/E of 174.34× is above the pharmaceuticals median (45.29×) while profit declined 74.2% last year.

Importance 62 / 95 · valuation

Section 03 · The company

Who is this company?

Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.

Market cap
₹59,329 cr
FY2026 revenue
₹16,927 cr
FY2026 net profit
₹369 cr
Net worth
₹36,622 cr
Total debt
₹14,825 cr
EPS (basic)
₹2.82
Listed
NSE · BSE
Reporting
Ind-ASApr–Mar

Peer set used on this page: 12 pharmaceuticals.

Section 04 · Business performance

Is the business growing?

Revenue grew 17.4% a year over 7 years, from ₹5,514 cr in FY2019 to ₹16,927 cr in FY2026. Net profit fell 13.3% a year over the same period, including a one-off charge of ₹403 cr; excluding it, a profit of about ₹772 cr.

Revenue & net profit — FY19 to FY26₹ crore · consolidated
₹'000 cr05101520012REVENUENET PROFIT6k1,003FY196k871FY207k846FY218k772FY2211k643FY2315k1,298FY2415k1,429FY2517k369FY26
RevenueNet profit
Watch

Revenue grew 10.9% but profit declined 74.2%, so the company kept less of each rupee of revenue as profit.

Rule PROFIT_SLOWER_THAN_REVENUE

Revenue growth per year
+17.4%over 7 years (FY19–FY26)
Revenue growth
+10.9%vs last year
Net profit growth
−74.2%vs last year
Change in net profit since FY19
−63%

Revenue grew 10.9% but EBITDA margin fell 6.2 percentage points to 22.4%, so the company kept less of each rupee of revenue as operating profit.

Profit has swung sharply over 7 years (from ₹369 to ₹1,429) — one year is a weak guide to the earnings power.

Revenue compounded at 17.4% a year over 7 years (₹5,514 → ₹16,927).

Net profit fell 74.2% year on year (FY2025 → FY2026).

Section 05 · Recent activity

What changed recently?

In Q2 FY27 (Jul–Sep 2026), revenue was ₹4,389 cr (up 2.2% on the same quarter last year) and net profit ₹57 cr (down 57.3%).

Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.

Concern

Q2 FY27 net profit was ₹57 cr, down 57.3% from ₹133 cr a year earlier.

Rule QTR_PROFIT_GROWTH_YOY

Watch

Q2 FY27 net profit declined 57.3% while revenue grew 2.2% vs the same quarter last year — a gap of 59.5 percentage points.

Rule QTR_PROFIT_VS_REVENUE_GROWTH

Concern

Q2 FY27 EBIT was ₹302 cr, down 33.8% from ₹455 cr a year earlier.

Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY

A. Quarterly results

Latest quarters — Q3 '25 to Q2 '27₹ crore · consolidated
₹'000 cr01345001REVENUENET PROFIT4k81Q3 '254k459Q4 '254k89Q1 '264k133Q2 '264k-52Q3 '265k199Q4 '264k137Q1 '274k57Q2 '27
RevenueNet profit
QuarterRevenueYoYNet profitYoYNet margin
Q3 FY253,821−3.3%81−89.2%2.1%
Q4 FY254,417+12.8%459+106.1%10.4%
Q1 FY263,942+14.8%89−89.6%2.3%
Q2 FY264,296+19.6%133+390.0%3.1%
Q3 FY264,173+9.2%−52−163.9%−1.2%
Q4 FY264,517+2.3%199−56.8%4.4%
Q1 FY274,336+10.0%137+53.4%3.2%
Q2 FY274,389+2.2%57−57.3%1.3%

B. TTM snapshot

Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters

Revenue
₹17,415 crTTM
EBITDA
₹3,791 crTTM
EBIT
₹1,651 crTTM
PBT
₹362 crTTM
Net profit
₹340 crTTM

C. Corporate actions

3 Jul 2026DividendFinal Dividend - Rs. - 0.5000 — ₹0.50/share
4 Jul 2025DividendFinal Dividend - Rs. - 0.5000 — ₹0.50/share
5 Jul 2024DividendFinal Dividend - Rs. - 0.5000 — ₹0.50/share
7 Jul 2023DividendFinal Dividend - Rs. - 1.5000 — ₹1.50/share
30 Jun 2022DividendFinal Dividend - Rs. - 0.5000 — ₹0.50/share
18 Jul 2019DividendFinal Dividend - Rs. - 0.5000 — ₹0.50/share
12 Jun 2019Bonus issueBonus issue 1:1 — 1:2
19 Jul 2018DividendFinal Dividend - Rs. - 1.0000 — ₹1.00/share
20 Jul 2017DividendFinal Dividend - Rs. - 1.0000 — ₹1.00/share
15 Jun 2017Bonus issueBonus issue 2:1 — 1:3
17 Mar 2016DividendInterim Dividend - Rs. - 5.0000 — ₹5.00/share
9 Apr 2015DividendInterim Dividend - Rs. - 5.0000 — ₹5.00/share
10 Jul 2014DividendFinal Dividend - Rs. - 5.0000 — ₹5.00/share
11 Jul 2013DividendSpecial Dividend - Rs. - 2.5000 — ₹2.50/share
11 Jul 2013DividendFinal Dividend - Rs. - 5.0000 — ₹5.00/share
5 Jul 2012DividendFinal Dividend - Rs. - 5.0000 — ₹5.00/share
7 Jul 2011DividendFinal Dividend - Rs. - 3.0000 — ₹3.00/share
5 May 2011DividendInterim Dividend - Rs. - 1.5000 — ₹1.50/share
8 Jul 2010DividendDividend - Rs. - 3.5000 — ₹3.50/share
8 Jul 2009DividendDividend - Rs. - 3.0000 — ₹3.00/share
11 Sept 2008Bonus issueBonus issue 1:1 — 1:2
3 Jul 2008DividendDividend - Rs. - 5.0000 — ₹5.00/share
Section 06 · Business performance

Is it becoming more profitable?

EBITDA margin was 22.4% in FY2026, against 27.9% in FY2019. ROE was 1.1% and ROCE 3.8% in FY2026.

Margins — FY19 to FY26% of revenue · consolidated
0%5%10%15%20%25%30%22.4%2.1%FY19FY20FY21FY22FY23FY24FY25FY26
EBITDA marginNet margin
Concern

ROCE has fallen for 6 consecutive years, from 13.6% to 3.8%.

Rule ROCE_DECLINING_STREAK

EBITDA margin now
22.4%
8-year range
22.4–28.7%
ROE FY2026
1.1%
ROCE FY2026
3.8%

EBITDA margin of 22.4% is the thinnest in 7 years (prior range 25.8% to 28.7%).

ROE of 1.1% is below the pharmaceuticals median of 14.4%.

ROE of 1.1% is the lowest in 7 years (prior range 4.0% to 14.9%).

ROE declined from 5.4% to 1.1% year on year.

Section 07 · Financial health

Is financial health improving?

Debt-to-equity was 0.40x in FY2026, against 0.27x in FY2019; interest coverage 1.86x. Operating cash flow was 5.41x net profit.

Net worth — FY19 to FY26₹ crore · consolidated
₹'000 cr01327407kFY197kFY209kFY219kFY2222kFY2325kFY2428kFY2537kFY26
Net worth (shareholders' funds)
Strength

Operating cash flow has matched or exceeded reported profit in 6 of the last 6 profit-making years (latest 5.41×).

Rule CFO_CONSISTENTLY_EXCEEDS_PAT

Operating cash flow vs net profit₹ crore · FY21–FY26
0k2k3k5k1k846FY211k772FY222k643FY233k1kFY244k1kFY252k369FY26
Operating cash flowNet profit
Total debt
₹14,825 cr
Operating cash flow ÷ net profit
5.41×FY2026
Free cash flow
₹196 cr
Current ratio
1.22×

Net worth compounded at 27.4% a year over 7 years (₹6,707 → ₹36,622) — though FY2023 saw a one-off step-change of 137% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.

Operating profit covers interest only 1.86× (FY2026).

Debt-to-equity fell from 0.64× to 0.40× year on year.

Section 08 · Relative position

How does it compare with peers?

Within its 12-company Pharmaceuticals peer group, it ranks 12 of 12 on return on equity and 11 of 12 on EBITDA margin. P/E is not meaningful this year because FY2026 profit is driven by a one-off charge.

Ranked against 12 pharmaceuticals (FY2026, consolidated).

Revenue growth

BIOCON · 9th of 12 · set median 14.8%

GLENMARK27.5%LUPIN23.1%LAURUSLABS22.7%TORNTPHARM21.4%MANKIND17.0%ZYDUSLIFE16.8%DIVISLAB12.8%SUNPHARMA11.2%BIOCON10.9%AUROPHARMA6.1%DRREDDY3.2%CIPLA2.2%

EBITDA margin

BIOCON · 11th of 12 · set median 28.7%

DIVISLAB37.4%SUNPHARMA33.7%ZYDUSLIFE33.1%LUPIN33.1%TORNTPHARM31.9%GLENMARK29.6%MANKIND27.8%LAURUSLABS26.9%CIPLA24.0%DRREDDY23.2%BIOCON22.4%AUROPHARMA21.8%

Return on equity

BIOCON · 12th of 12 · set median 14.4%

LUPIN26.9%ZYDUSLIFE18.3%LAURUSLABS17.7%TORNTPHARM17.0%DIVISLAB16.2%SUNPHARMA14.7%GLENMARK14.1%MANKIND12.5%CIPLA11.7%DRREDDY11.5%AUROPHARMA9.9%BIOCON1.1%

P/E ratio

BIOCON · 12th of 12 · set median 45.3×

LUPIN17.6×AUROPHARMA26.2×ZYDUSLIFE28.1×CIPLA40.1×SUNPHARMA41.2×DRREDDY42.1×MANKIND48.5×GLENMARK51.5×TORNTPHARM75.8×DIVISLAB88.3×LAURUSLABS93.0×BIOCON174.3×
Watch

The P/E of 174.34× is above the pharmaceuticals median (45.29×) while profit declined 74.2% last year.

Rule PRICED_FOR_GROWTH

P / E
174.3×TTM to Sept 26
P / B
1.6×latest book
P / S
3.4×TTM sales
Earnings yield
0.6%TTM to Sept 26

On the trailing twelve months. Last full year: P/E 160.9× · P/S 3.4× · ROE 1.1%.

Section 09 · The stock

How has the stock performed?

The share price is down 7.4% over 1 year, up 56.6% over 3 years (16.1% a year) and down 0.3% over 5 years (−0.1% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 17.0% below its 52-week high.

Adjusted close — 2020-01 to 2026-11₹ per share · split / bonus adjusted
0k₹3662020202120222023202420252026

Long-term price performance is shown above.

1-year return
−7.4%
3-year return
+56.6%
5-year return
−0.3%
From 52-wk high
−17.0%
Section 10 · Technical data

What does the technical data say?

Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.

vs 50-day avg
Above₹363
vs 200-day avg
Below₹390
RSI (14)
55.9neutral
MACD histogram
1.9
From 52-wk high
−17.0%
From 52-wk low
+12.1%
30-day volatility
28.5%ann.
6-month return
−15.4%
RSI (14) · 0–10055.9 — neutral
0305070100OVERSOLDOVERBOUGHT55.9
Section 11 · Open questions

What should I investigate further?

Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.

  • Watch
    Profit lagging revenue
    Revenue grew 10.9% but profit declined 74.2%, so the company kept less of each rupee of revenue as profit.
    PROFIT_SLOWER_THAN_REVENUE · conviction 74
  • Watch
    Sharp margin drop
    EBITDA margin dropped 6.2 percentage points in a single year, from 28.7% to 22.4% — worth investigating.
    MARGIN_SHARP_DROP · conviction 70
  • Watch
    Growing, but less profitably
    Revenue grew 10.9% but EBITDA margin fell 6.2 percentage points to 22.4%, so the company kept less of each rupee of revenue as operating profit.
    REVENUE_UP_MARGIN_DOWN · conviction 69
  • Concern
    Capital efficiency slipping
    ROCE has fallen for 6 consecutive years, from 13.6% to 3.8%.
    ROCE_DECLINING_STREAK · conviction 69
  • Watch
    Premium valuation, soft growth
    The P/E of 174.34× is above the pharmaceuticals median (45.29×) while profit declined 74.2% last year.
    PRICED_FOR_GROWTH · conviction 62
  • Concern
    Margins at a multi-year low
    EBITDA margin of 22.4% is the thinnest in 7 years (prior range 25.8% to 28.7%).
    MARGIN_AT_MULTI_YEAR_LOW · conviction 59
  • Concern
    Less profitable than peers
    ROE of 1.1% is below the pharmaceuticals median of 14.4%.
    ROE_BELOW_PEER_MEDIAN · conviction 59
  • Concern
    Returns at a multi-year low
    ROE of 1.1% is the lowest in 7 years (prior range 4.0% to 14.9%).
    ROE_AT_MULTI_YEAR_LOW · conviction 58
  • Watch
    Volatile earnings
    Profit has swung sharply over 7 years (from ₹369 to ₹1,429) — one year is a weak guide to the earnings power.
    EARNINGS_VOLATILE · conviction 57
  • Concern
    Profit fell
    Net profit fell 74.2% year on year (FY2025 → FY2026).
    PROFIT_DECLINED_YOY · conviction 54
  • Watch
    Reported profit carries a one-off
    FY2026 pre-tax profit includes a ₹403 exceptional charge (90.0% of PBT) — the underlying trend differs from the reported number.
    PROFIT_INCLUDES_EXCEPTIONALS · conviction 48
  • Concern
    Returns declining
    ROE declined from 5.4% to 1.1% year on year.
    ROE_DETERIORATED_YOY · conviction 44
  • Concern
    Thin interest cover
    Operating profit covers interest only 1.86× (FY2026).
    INTEREST_COVER_LOW · conviction 43
  • Cash-flow-statement facts are unavailable for FY2019, FY2020 — those filings predate SEBI's Cash Flow Statement disclosure requirement. All other loaded years carry full P&L, balance sheet and cash-flow data.
Section 12 · Reference

The numbers

The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.

Income & balance sheet — ₹ crore, consolidated
MetricFY19FY20FY21FY22FY23FY24FY25FY26
Revenue5,5146,3677,1068,18411,17414,75615,26216,927
Total income5,6596,5297,3608,39711,55015,62116,47017,270
EBITDA1,5381,7651,9072,1832,8884,1644,3753,798
Profit before tax1,2141,2151,1471,1901,0641,6091,887448
Net profit1,0038718467726431,2981,429369
EPS (₹)15.36.36.25.43.98.68.52.8
Net worth6,7077,3838,5089,47022,48925,27527,71336,622
Total debt1,8031,8903,5564,90417,77115,73017,75614,825
Operating cash flow——1,1601,1771,8532,9544,0611,994
Free cash flow——−357−5192601,2971,925196
Key ratios — consolidated
RatioFY19FY20FY21FY22FY23FY24FY25FY26
Growth
Revenue growth YoY—15.511.615.236.532.13.410.9
Profit growth YoY—-13.1-2.8-8.8-16.7101.810.1-74.2
Profitability
EBITDA margin %27.927.726.826.725.828.228.722.4
Net margin %17.713.311.59.25.68.38.72.1
Return on equity %14.912.410.78.64.05.45.41.1
Return on capital %12.813.611.210.46.56.46.23.8
Leverage & cash
Debt to equity0.270.260.420.520.790.620.640.40
Cash flow ÷ profit——1.371.522.882.282.845.41
Current ratio1.591.331.812.191.450.991.141.22
Financials: BSE Integrated Filing inline XBRL (SEBI taxonomy), normalised to standard metric keys. Prices: end-of-day — history loaded from NSE end-of-day files, new days from the BSE bhavcopy; raw OHLC preserved; a corporate-action factor produces the adjusted series. The insight engine writes factual observations from fixed rules — it does not make recommendations. Not investment advice.